A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients With Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study
PRIMARY OBJECTIVES:
I. To evaluate the safety, tolerability, and to establish the maximum tolerated recommended
dose (RD) CCI-779 (temsirolimus) in cohorts of patients with varying degrees of hepatic
dysfunction (mild, moderate, and severe) in order to provide appropriate dosing
recommendations for CCI-779 (temsirolimus) in this population.
SECONDARY OBJECTIVES:
I. To characterize the pharmacokinetic (PK) profile of CCI-779 (temsirolimus) in patients
with varying degrees of hepatic function.
II. To determine if the pharmacodynamic (PD) profile of CCI-779 (temsirolimus) as measured
by drug effects on p70s6 kinase and p4EBP1 phosphorylation and other markers of mTOR
inhibition in peripheral blood mononuclear cells (PBMC) is altered in patients with varying
degrees of hepatic function.
III. To document the non-dose limiting toxicities and any anti-tumor efficacy associated
with administration of CCI-779 (temsirolimus) in this patient population.
IV. To compare the NCI ODWG criteria and the Child-Pugh classification of hepatic
dysfunction in terms of their predictive value in reducing interpatient variability in the
PK and PD of CCI-779 (temsirolimus).
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to
hepatic function (normal vs mild dysfunction vs moderate dysfunction vs severe dysfunction
vs liver transplant).
Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat
every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.
After completion of study treatment, patients are followed periodically for 30 days.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
RD, defined as the highest dose level at which less than 33% of at least six patients experience DLT
28 days
Yes
John Sarantopoulos
Principal Investigator
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
United States: Food and Drug Administration
NCI-2012-03108
NCT00275093
December 2005
Name | Location |
---|---|
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio | San Antonio, Texas 78229 |